

1 **Detection of Air and Surface Contamination by Severe Acute Respiratory Syndrome**  
2 **Coronavirus 2 (SARS-CoV-2) in Hospital Rooms of Infected Patients**

3 Po Ying Chia, MBBS<sup>1,2,3</sup> \*; Kristen Kelli Coleman, PhD<sup>4</sup> \*; Yian Kim Tan, PhD<sup>5</sup> \*; Sean Wei  
4 Xiang Ong<sup>1,2</sup> \*, Marcus Gum, BSc<sup>5</sup>; Sok Kiang Lau, PhD<sup>5</sup>; Stephanie Sutjipto, MBBS<sup>1,2</sup>; Pei  
5 Hua Lee, MBBS<sup>1,2</sup>; Than The Son, DVM<sup>4</sup>; Barnaby Edward Young, MB Bchir<sup>1,2,3</sup>; Donald  
6 K. Milton, MD, DrPH<sup>6</sup>; Gregory C. Gray, MD<sup>4,7,8</sup>; Stephan Schuster, PhD<sup>9</sup>; Timothy  
7 Barkham, MBBS<sup>2,10</sup>; Partha Prathim De, MBBS<sup>2,3</sup>; Shawn Vasoo, MBBS<sup>1,2,3</sup>; Monica Chan,  
8 BMBS<sup>1,2</sup>; Brenda Sze Peng Ang, MBBS, MPH<sup>1,2,3,10</sup>; Boon Huan Tan, PhD<sup>5</sup>; Yee-Sin Leo,  
9 MBBS, MPH<sup>1,2,3,10</sup>; Oon-Tek Ng, MBBS, MPH<sup>1,2,3</sup> #; Michelle Su Yen Wong, PhD<sup>5</sup> #; and  
10 Kalisvar Marimuthu, MBBS<sup>1,2,10</sup> #

11 \* These four first authors contributed equally.

12 # These three senior authors contributed equally.

13 **Author Affiliations:**

14 <sup>1</sup> National Centre for Infectious Diseases, Singapore

15 <sup>2</sup> Tan Tock Seng Hospital, Singapore

16 <sup>3</sup> Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

17 <sup>4</sup> Duke-NUS Medical School, National University of Singapore

18 <sup>5</sup> DSO National Laboratories, Singapore

19 <sup>6</sup> Maryland Institute for Applied Environmental Health, University of Maryland School of  
20 Public Health, USA

21 <sup>7</sup> School of Medicine and Global Health Institute, Duke University, USA

22 <sup>8</sup> Global Health Research Center, Duke Kunshan University, Kunshan, China

23 <sup>9</sup> Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological  
24 University, Singapore

25 <sup>10</sup> Yong Loo Lin School of Medicine, National University of Singapore

26 **Corresponding Authors:**

27 Kalisvar Marimuthu, National Centre for Infectious Diseases, 16 Jln Tan Tock Seng,  
28 Singapore 308442; (kalisvar\_marimuthu@ncid.sg) (+65) 6357 7924)

29 Oon-Tek Ng, National Centre for Infectious Diseases, 16 Jln Tan Tock Seng, Singapore  
30 308442; (Oon\_Ng\_Tek@ncid.sg) (+65) 6357 7924)

31 **Running Title:** Air and surface contamination by SARS-CoV-2

32 **Word Count:** 270 (abstract), 2456 (manuscript)

33 **Abstract:**

34 **Background:** Understanding the particle size distribution in the air and patterns of  
35 environmental contamination of SARS-CoV-2 is essential for infection prevention policies.

36 **Objective:** To detect the surface and air contamination by SARS-CoV-2 and study the  
37 associated patient-level factors.

38 **Design:** Cross-sectional study.

39 **Setting:** Airborne infection isolation rooms (AIIRs) at the National Centre for Infectious  
40 Diseases, Singapore.

41 **Patients:** COVID-19 inpatients with a positive PCR test for SARS-CoV-2 within 72 hours  
42 before the environmental sampling.

43 **Measurements:** Extent of environmental surface contamination in AIIRs of 30 COVID-19  
44 patients by PCR on environmental swabs. The particle size distribution of SARS-CoV-2 in  
45 the air was measured using NIOSH air samplers.

46 **Results:** 245 surface samples were collected from 30 rooms of COVID-19 patients, and air  
47 sampling was conducted in 3 rooms. 56.7% of the rooms had at least one environmental  
48 surface contaminated, with 18.5% of the toilet seats and toilet flush button being  
49 contaminated. High touch surface contamination was shown in ten (66.7%) out of 15 patients  
50 in the first week of illness, and three (20%) beyond the first week of illness ( $p = 0.010$ ). Air  
51 sampling of two COVID-19 patients (both day 5 of symptoms) detected SARS-CoV-2 PCR-  
52 positive particles of sizes  $>4 \mu\text{m}$  and  $1-4 \mu\text{m}$ . In a single subject at day 9 of symptoms, no  
53 SARS-CoV-2 PCR-positive particles were detected.

54 **Limitations:** Viral culture results were not available to assess the viability of the virus  
55 contaminating the air and surface.

56 **Conclusion:** Environmental contamination was detected in rooms with COVID-19 patients in  
57 early stages of illness, but was significantly less after day 7 of disease. Under AIIR  
58 conditions, SARS-CoV-2 respiratory particles can be detected at sizes 1-4  $\mu\text{m}$  and  $>4 \mu\text{m}$  in  
59 diameter in the air which warrants further studies.

## 60 **Introduction**

61 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease  
62 2019 (COVID-19) has spread globally and many countries are experiencing ongoing local  
63 transmission despite varying levels of control efforts. Understanding the different  
64 transmission routes of SARS-CoV-2 is crucial in planning effective interventions to break the  
65 chain of transmission. Although extensive surface contamination with SARS-CoV-2 by a  
66 symptomatic patient has been demonstrated (1), little is known about airborne transmission of  
67 SARS-CoV-2. It is also unknown if asymptomatic individuals pose the same environmental  
68 contamination risk as symptomatic ones, although viral shedding has been demonstrated to  
69 continue even after clinical recovery of COVID-19 patients (2). There are multiple reports of  
70 asymptomatic patients testing positive for SARS-CoV-2 (3, 4), and the potential transmission  
71 of the virus by an asymptomatic person has been described (5). Therefore, viral  
72 contamination of the air and surfaces surrounding asymptomatic or recovering COVID-19  
73 patients could have serious implications for outbreak control strategies. This knowledge gap  
74 is recognized in the Report of the WHO-China Joint Mission on Coronavirus 2019 (6).

75 The primary objective of our study was to identify potential patient-level risk factors for  
76 environmental contamination by SARS-CoV-2 by sampling the air and surfaces surrounding  
77 hospitalized COVID-19 patients at different stages of illness.

## 78 **Methods**

### 79 **Study design, patient selection and data collection**

80 We conducted this cross-sectional study in airborne infection isolation rooms (AIIRs) at the  
81 National Centre for Infectious Diseases, Singapore. These rooms had 12 air exchanges per  
82 hour, an average temperature of 23°C, relative humidity of 53 – 59%, and exhaust flow of  
83 579.6 m<sup>3</sup>/h.

84 Patients with a SARS-CoV-2 infection confirmed by a polymerase chain reaction (PCR)-  
85 positive respiratory sample within the prior 72 hours were included. Clinical characteristics,  
86 including the presence of symptoms, day of illness, day of stay in the room, supplemental  
87 oxygen requirement, and baseline characteristics, were collected. One patient from a  
88 previously published pilot study on environmental sampling in the same facility (Patient 30;  
89 Supplemental Table 1) was also included in the current analysis (1).

### 90 **Cleaning regimen of rooms**

91 Routine environmental cleaning of the rooms was carried out by a trained team of  
92 housekeeping staff. High-touch surfaces (e.g. bed rail, cardiac table, switches) were cleaned  
93 twice daily using 5000 parts per million (ppm) sodium dichloroisocyanurate (NaDCC),  
94 reconstituted using Biospot<sup>®</sup> Effervescent Chlorine Tablets. The floor was cleaned daily  
95 using 1000ppm NaDCC. All surface sampling was performed in the morning before the first  
96 cleaning cycle for the day.

### 97 **Air sampling**

98 Six NIOSH BC 251 bioaerosol samplers were placed in each of three AIIRs in the general  
99 ward to collect air samples. Particles collected with the NIOSH sampler are distributed into  
100 three size fractions. Particles  $>4 \mu\text{m}$  in diameter are collected in a 15 mL centrifuge tube,  
101 particles 1-4  $\mu\text{m}$  in diameter are collected in a 1.5 mL centrifuge tube, and particles  $<1 \mu\text{m}$  in  
102 diameter are collected in a self-assembled filter cassette containing a 37-mm diameter,  
103 polytetrafluoroethylene (PTFE) filter with 3 $\mu\text{m}$  pores. All NIOSH samplers were connected  
104 to either SKC AirCheck TOUCH Pumps or SKC Universal air sampling pumps set at a flow-  
105 rate of 3.5 L/min and run for four hours, collecting a total of 5,040 L of air from each  
106 patient's room.

107 In the room of Patient 1, three NIOSH samplers were attached to each of two tripod stands  
108 and situated at different heights from the ground (1.2m, 0.9m, and 0.7m) near the air exhaust  
109 to capture particles from the unidirectional airflow in the room. Throughout the four-hour  
110 sampling period, Patient 1 was intermittently facing the NIOSH samplers while seated one  
111 meter from the first tripod and 2.1 meters from the second tripod. Four SKC 37mm PTFE  
112 filter (0.3 $\mu$ m pore size) cassettes were also distributed throughout the room and connected to  
113 SKC Universal air sampling pumps set at a flow-rate of 5 L/min, each collecting an  
114 additional 1,200 L of air from the room.

115 In the rooms of Patients 2 and 3, three NIOSH samplers were attached to each of two tripod  
116 stands and situated at different heights from the ground (1.2m, 0.9m, and 0.7m). Throughout  
117 the four-hour sampling period, Patients 2 and 3 remained in bed within 1 meter from all 6  
118 NIOSH samplers (Supplementary Figure 1). Patient 3 was also talking on the phone for a  
119 significant proportion of time during sampling. Additional SKC pumps with PTFE filter  
120 cassettes were not used in the rooms of Patient 2 and 3.

121 The 6 NIOSH samples from each room were pooled prior to analysis, but the particle size  
122 fractions remained separated. Each sample pool was representative of 5,040 L air.

### 123 **Surface sampling**

124 Surface samples were collected with Puritan® EnviroMax Plus pre-moistened macrofoam  
125 sterile swabs (25-88060). Eight to 20 surface samples were collected in each room. Five were  
126 high-touch surfaces, including the cardiac table, entire length of the bed rails including bed  
127 control panel and call bell, bedside locker, electrical switches on top of the beds, and chair in  
128 general ward rooms (Supplemental Figure 1). In ICU rooms, the ventilator and infusion  
129 pumps were sampled instead of the electrical switches on top of the beds and chair  
130 (Supplemental Figure 2). Air exhaust outlets and glass window surfaces were sampled in five

131 rooms, including the three rooms in which air sampling was performed. Toilet seat and  
132 automatic flush button (one combined swab) were sampled in AIIR rooms in the general  
133 ward.

#### 134 **Sample transfer and processing**

135 All samples were immediately stored at 4°C in the hospital prior to transfer to a BSL-3  
136 laboratory where samples were immediately processed and stored at -80°C unless directly  
137 analyzed. Prior to RNA extraction, NIOSH aerosol sample tubes and filters were processed as  
138 previously described (7), with slight modification due to the pooling of samples.

#### 139 **Laboratory methods**

140 The QIAamp viral RNA mini kit (Qiagen Hilden, Germany) was used for sample RNA  
141 extraction. Real-time PCR assays targeting the envelope (E) genes (8) and an in house orflab  
142 assay were used to detect SARS-CoV-2 in the samples (9). All samples were run in duplicate  
143 and with both assays. Positive detection was recorded as long as amplification was observed  
144 in at least 1 assay.

#### 145 **Statistical analysis**

146 Statistical analysis was performed using Stata version 15.1 (StataCorp, College Station,  
147 Texas) and GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego).  $P < 0.05$  was  
148 considered statistically significant, and all tests were 2-tailed. For the surface environment,  
149 outcome measures analyzed were any positivity by room and pooled percentage positivity by  
150 day of illness and respiratory viral load (represented by clinical cycle threshold (Ct) value).  
151 We analyzed the factors associated with environmental contamination using the Student t-  
152 test, or the nonparametric Wilcoxon rank-sum test was used for continuous variables  
153 depending on their distribution. The  $\chi^2$  or Fisher exact test was used to compare categorical

154 variables. We plotted the best fit curve by least-square method to study the environmental  
155 contamination distribution across various the days of illness and clinical Ct value.

## 156 **Results**

157 Environmental sampling was conducted in three AIIRs in the ICU and 27 AIIRs in the  
158 general ward. Air sampling was performed in three of the 27 AIIRs in the general ward. All  
159 patients reported COVID-19 symptoms. Seven patients (23%) were asymptomatic at the time  
160 of environmental sampling. Of the 23 symptomatic patients, 18 (78%) had respiratory  
161 symptoms, one had gastrointestinal symptoms, one had both respiratory and gastrointestinal  
162 symptoms, and three patients (10%) had fever or myalgia only (Supplemental Table 1).

163 There were no baseline differences between patients with environmental surface  
164 contamination and those without, in terms of age, comorbidities, and positive clinical sample  
165 on the day of sampling. Median cycle threshold (Ct) values of the clinical specimens for  
166 patients with and without environmental surface contamination were 25.69 (IQR 20.37 to  
167 34.48) and 33.04 (28.45 to 35.66) respectively (Table 1).

168 Of the rooms with environmental contamination, the floor was most likely to be contaminated  
169 (65%), followed by the bed rail (59%), and bedside locker (42%) (Figure 1). Contamination  
170 of toilet seat and automatic toilet flush button was detected in five out of 27 rooms, and all  
171 five occupants had reported gastrointestinal symptoms within the preceding one week of  
172 sampling. We did not detect surface contamination in any of the three ICU rooms.

173 Presence of environmental surface contamination was higher in week 1 of illness (Figure 2)  
174 and showed association with the clinical cyclical threshold ( $P=0.06$ ). Surface environment  
175 contamination was not associated with the presence of symptoms or supplementary oxygen  
176 (Table 1). In a subgroup analysis, the presence and extent of high-touch surface  
177 contamination were significantly higher in rooms of patients in their first week of illness

178 (Figure 2). The best fit curve with the least-squares fit (Figure 3) showed that the extent of  
179 high-touch surface contamination declined with increasing duration of illness and Ct values.  
180 There was also no correlation between the Ct values of clinical samples and the Ct values of  
181 environmental samples across the days of illness (Supplemental Figure 3).

182 Air samples from two (66.7%) of three AIIRs tested positive for SARS-CoV-2, in particle  
183 sizes  $>4 \mu\text{m}$  and  $1-4 \mu\text{m}$  in diameter (Table 1). Total SARS-CoV-2 concentrations in air  
184 ranged from  $1.84 \times 10^3$  to  $3.38 \times 10^3$  RNA copies per  $\text{m}^3$  air sampled. Rooms with viral  
185 particles detected in the air also had surface contamination detected.

## 186 **Discussion**

187 Surface sampling revealed that the PCR-positivity high-touch surfaces was associated with  
188 nasopharyngeal viral loads and peaked at approximately day four to five of symptoms. Air  
189 sampling of the AIIR environments of two COVID-19 patients (both day five of illness with  
190 high nasopharyngeal swab viral loads) detected the presence of SARS-CoV-2 particles sized  
191  $1-4 \mu\text{m}$  and  $> 4 \mu\text{m}$ . The absence of any detection of SARS-CoV-2 in air samples of the third  
192 patient (day nine of illness with lower nasopharyngeal viral load concentration) suggests that  
193 the presence of SARS-CoV-2 in the air is possibly highest in the first week of illness.

194 Recent aggregated environmental sampling and laboratory experiments have examined the  
195 particle size distribution of SARS-CoV-2 in the air. A study from Wuhan, China sampled  
196 three different environmental settings and detected aerosol size range particles (10).

197 Additionally, a recent laboratory study demonstrated the ability of SARS-CoV-2 to remain  
198 viable in aerosols for up to 3 hours (11). While limited in subject numbers, our study  
199 examined this issue at the individual patient-level, thus enabling correlation of particle size  
200 distribution in the air with symptoms duration and nasopharyngeal viral loads. The absence of  
201 aerosol-generating procedures or intranasal oxygen supplementation reduces the possibility

202 of our current findings being iatrogenic in nature. Larger individual patient-level studies  
203 examining the droplet and aerosolizing potential of SARS-CoV-2 over different distances and  
204 under different patient and environmental conditions are rapidly needed to determine the  
205 generalizability of our current findings.

206 In the current analysis the presence and concentration of SARS-CoV-2 in air and high-touch  
207 surface samples correlated with the day of illness and nasopharyngeal viral loads of COVID-  
208 19 patients. This finding is supported by multiple observational clinical studies have  
209 demonstrated that SARS-CoV-2 viral loads peak in the first week among COVID-19 patients  
210 (2, 12, 13). This finding could help inform public health and infection prevention measures in  
211 prioritizing resources by risk stratifying COVID-19 patients by their potential to directly or  
212 indirectly transmit the SARS-CoV-2 virus to others.

213 Our study was limited in that it did not determine the ability of SARS-CoV-2 to be cultured  
214 from the environmental swabs and the differentially-sized air particles which would be vital  
215 to determining the infectiousness of the detected particles. Another study from Nebraska  
216 attempted virus culture on SARS-CoV-2 PCR-positive air samples, however could not isolate  
217 viable virus (14). The difficulty in culturing virus from air samples arises from low virus  
218 concentrations, as well as the compromised integrity of the virus due to air sampling  
219 stressors. Future studies using enhanced virus culture techniques could be considered (15),  
220 and efforts to design a culture method to isolate virus from our samples is underway. Second,  
221 sampling in an AIIR environment may not be representative of community settings and  
222 further work is needed to generalize our current findings. Third, we sampled each room at a  
223 single timepoint during the course of illness and did not track environmental contamination  
224 over the course of illness for individual patients. Fourth, as clinical results were within 72  
225 hours of environmental testing, it is plausible that during the day of testing, viral load was  
226 actually low or negligible, hence limiting environmental contamination.

227 Current epidemiologic evidence does not seem to point to aerosolization as the key route of  
228 transmission of SARS-CoV-2 (16). Detailed epidemiologic studies of outbreaks, in both  
229 healthcare and non-healthcare settings, should be carried out to determine the relative  
230 contribution of various routes of transmission and their correlation with patient-level factors.

231 In conclusion, in a limited number of AIIR environments, our current study involving  
232 individual COVID-19 patients not undergoing aerosol-generating procedures or oxygen  
233 supplementation suggest that SARS-CoV-2 can be shed in the air from a patient in particles  
234 sized between 1 to 4 microns. Even though particles in this size range have the potential to  
235 linger longer in the air, more data on viability and infectiousness of the virus would be  
236 required to confirm the potential airborne spread of SARS-CoV-2. Additionally, the  
237 concentrations of SARS-CoV-2 in the air and high-touch surfaces could be highest during the  
238 first week of COVID-19 illness. Further work is urgently needed to examine these findings in  
239 larger numbers and different settings to better understand the factors affecting air and surface  
240 spread of SARS-CoV-2 and inform effective infection prevention policies.

241 **Acknowledgements**

242 We thank Dr Bill Lindsley (National Institute for Occupational Safety and Health, NIOSH)  
243 for loaning us aerosol samplers and guiding us in their use; Dr. Raquel Binder and Emily  
244 Robie from the Duke One Health team for quickly providing us equipment for use in this  
245 study; Dr Hsu Li Yang (Saw Swee Hock School of Public Health, National University of  
246 Singapore) for facilitating the air sampling; and Dr Ding Ying (National Centre for Infectious  
247 Diseases, Singapore) for helping with project coordination. No compensation was received  
248 for their roles in the study.

249 We further thank the colleagues in DSO National Laboratories in the environmental detection  
250 team and clinical diagnostics team for BSL3 sample processing and analysis as well as the  
251 logistics and repository team for transport of biohazard material, inventory and safekeeping  
252 of received items.

253

254 **Conflict of Interest Disclosures**

255 None reported.

256

257 **Funding**

258 This study is funded by NMRC Seed Funding Program (TR19NMR119SD), NMRC COVID-  
259 19 Research Fund (COVID19RF-001) and internal funds from DSO National Laboratories.  
260 Ng OT is supported by NMRC Clinician Scientist Award (MOH-000276). K Marimuthu is  
261 supported by NMRC CS-IRG (CIRG18Nov-0034). Chia PY is supported by NMRC  
262 Research Training Fellowship (NMRC/Fellowship/0056/2018).

263

264 **Role of Funder/Sponsors**

265 The funders had no role in the design and conduct of the study; collection, management,  
266 analysis and interpretation of the data; preparation, review or approval of the manuscript; and  
267 decision to submit the manuscript for publication.

## 268 **References**

- 269 1. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, Surface  
270 Environmental, and Personal Protective Equipment Contamination by Severe Acute  
271 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient.  
272 JAMA. 2020.
- 273 2. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic  
274 Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.  
275 JAMA. 2020.
- 276 3. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of  
277 pneumonia associated with the 2019 novel coronavirus indicating person-to-person  
278 transmission: a study of a family cluster. *The Lancet*. 2020.
- 279 4. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family  
280 cluster with SARS-CoV-2 infection. *Lancet Infect Dis*. 2020.
- 281 5. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic Carrier  
282 Transmission of COVID-19. *JAMA*. 2020.
- 283 6. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019  
284 (COVID-19). 2020.
- 285 7. Coleman KK, Sigler WV. Airborne Influenza A Virus Exposure in an Elementary  
286 School. *Scientific Reports*. 2020;10(1):1859.
- 287 8. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection  
288 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*.  
289 2020;25(3):2000045.
- 290 9. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic  
291 Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.  
292 JAMA. 2020.

- 293 10. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic Characteristics  
294 and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during  
295 COVID-19 Outbreak. *BioRxiv*. 2020.
- 296 11. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson  
297 BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-  
298 CoV-1. *New England Journal of Medicine*. 2020.
- 299 12. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load  
300 in Upper Respiratory Specimens of Infected Patients. *N Engl J Med*. 2020.
- 301 13. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in  
302 Different Types of Clinical Specimens. *JAMA*. 2020.
- 303 14. Santarpia JL, Rivera DN, Herrera V, Morwitzer MJ, Creager H, Santarpia GW, et al.  
304 Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University  
305 of Nebraska Medical Center. *medRxiv*. 2020.
- 306 15. Cao G, Noti J, Blachere F, Lindsley W, Beezhold D. Development of an improved  
307 methodology to detect infectious airborne influenza virus using the NIOSH bioaerosol  
308 sampler. *Journal of Environmental Monitoring*. 2011;13(12):3321-8.
- 309 16. Ng K, Poon BH, Kiat Puar TH, Shan Quah JL, Loh WJ, Wong YJ, et al. COVID-19  
310 and the Risk to Health Care Workers: A Case Report. *Ann Intern Med*. 2020.

311

312 **Tables & Figures**

313 **Table 1. Airborne severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)**  
314 **detections in hospital rooms of infected patients**

<b>Patient</b>	<b>Day of illness</b>	<b>Symptoms on day of air sampling</b>	<b>Clinical Ct value*</b>	<b>Airborne SARS-CoV-2 concentrations (RNA copies m<sup>-3</sup> air)</b>	<b>Aerosol particle size</b>	<b>Samplers used</b>
1	9	Cough, nausea, dyspnea	33.22	ND	--	NIOSH
				ND	--	SKC Filters
2	5	Cough, dyspnea	18.45	2,000	>4 μm	NIOSH
				1,384	1-4 μm	
3	5	Asymptomatic <sup>†</sup>	20.11	927	>4 μm	NIOSH
				916	1-4 μm	

ND = none detected

\*PCR cycle threshold value from patient's clinical sample

<sup>†</sup>Patient reported fever, cough, and sore throat until the day before the sampling. Patient reported no symptoms on the day of sampling, however was observed to be coughing during sampling


316 **Table 2: Baseline clinical characteristics of COVID-19 patients with environmental**  
317 **contamination**

	<b>With surface environment contamination (n=17)</b>	<b>Without surface environment contamination (n=13)</b>	<b>P-value</b>
Median age (IQR)	52 (42 to 62)	44 (36 to 55)	0.7535
Male Sex (%)	6 (46%)	8 (47%)	0.961
Median Age Adjusted Charlson's Comorbidity Index (IQR)	1 (0 to 2)	1 (0 to 1)	0.6924
Median day of Illness (IQR)	5 (4 to 9)	13 (5 to 20)	0.1715
Median day of stay in room (IQR)	3 (3 to 8)	4 (2 to 16)	0.9491
Oxygen requirement (%)	0	4 (31)	0.026
Symptomatic (%)	12 (71)	11 (85)	0.427
Respiratory symptoms (%)	11 (65)	7 (54)	0.547
Gastrointestinal symptoms (%)	1 (6)	1 (8)	1.000
Clinical Cycle threshold value, median (IQR)*	25.69 (20.37 to 34.48)	33.04 (28.45 to 35.66)	0.056

318 \*PCR cycle threshold value from patient's clinical sample

319

320 **Figure 1: Percentage of contaminated swabs from surface samples, in rooms with any**  
321 **contamination**



322 All other sites were n=17, except for air exhaust vents where n=5

323

324

325

326


327

328

329



330

331 **Figure 2: 2a. Percentage of patients with contamination of high touch surfaces in in the**  
332 **first week of illness compared with more than first week of illness. 2b. Percentage of**  
333 **surfaces contaminated across weeks of illness. 2c. Percentage of high-touch surfaces**  
334 **contaminated across weeks of illness**



335

336 **Figure 3: 3a. Mean percentage of high touch surface contaminated by day of illness with**  
337 **95% confidence interval with best fit curve. 3b. Percentage of high touch surfaces**  
338 **contaminated by clinical cycle threshold values with best fit curve. 3c. Mean percentage**  
339 **of high touch surface contaminated by day of illness with 95% confidence interval**



340 **grouped by symptoms**

341

342

343

344

345

